SUBSCRIBE

Breaking News on Supplements, Health & Nutrition - Europe US edition | APAC edition

News > Suppliers

Read more breaking news

 

 

Special infant formula ‘sometimes the only option’ for ill babies: Meiji

By Mark Astley+

30-Apr-2014
Last updated on 02-May-2014 at 10:37 GMT2014-05-02T10:37:51Z

Special infant formula ‘sometimes the only option’ for ill babies

Infant formula products developed specifically for babies with certain disorders are “often the best, and sometimes the only option,” Japanese dairy giant Meiji has claimed.

Tokyo-based Meiji and its Japanese rivals, Morinaga and MegMilk Snow Brand, manufacture a wide range of 'special needs' infant formula products that are “priced, supported and sold in cooperation” with the country’s government.

Among those developed by Meiji are infant formulae specifically for babies that suffer from conditions including cystic fibrosis, heart and kidney disease, and lipid malabsoprtion disease.

Speaking with DairyReporter.com, Richard Walton, R&D manager at Meiji, said that while it and its rivals would never promote 'special needs' products, breast is not necessarily best in 100% of cases.

“…some disorders result in infants not being able to breast feed,” said Walton.

“It is very important to emphasize that the companies that participate in this activity never promote formula over mother’s milk.”

“However, for infants suffering from the specific disorders covered, these special formulas are often these best and sometimes the only option,” he said.

"Partially compensated"

Meiji currently boasts a ‘special needs’ infant formula portfolio of 27 products, which it separates into three categories – registered special formula, unregistered special formula, and marketed products.

The registered and unregistered products are available for free “only through doctor’s offices”

“They are offered free upon prescription from a pediatrician,” said Walton.

As an example, Meiji manufactures a product to meet the needs of infants suffering with cystic fibrosis.

Health organizations, including the British National Health Service (NHS ), recommend that infants suffering from cystic fibrosis are breastfed, but acknowledge that if a baby is not gaining enough weight “a high-energy formula may be needed.”

Meiji’s solution for infants with cystic fibrosis is a medium chain triglyceride (MCT) amino acid formula, which has been reported to be useful in assisting growth and physiological development.

This product falls into Meiji’s registered special formula category, meaning that the company is “partially compensated by the government” for developing the product. It is, however, “not compensated at all” for the unregistered special formula products it produces for ailments such as lipid malabsorption disease, pediatric intractable epilepsy, and heart and kidney disease.

Meiji's marketed products, which are produced to meet the needs of infants that suffer from afflictions such as lactose intolerance, milk and egg allergies, and intractable diarrhoea, can be found with other standard infant formula products in stores and online in Japan.

Social responsibility

Responsibility for "little-used products" is a job shared by Meiji, Morinaga and MegMilk Snow Brand, who Walton said “divide responsibilities.”

“Our lines in this area do not completely overlap,” said Walton.

“On little-used products, the companies divide responsibilities so as not to double or triple development expenses.”

With little or no money to be made from these products, why does Meiji invests time and money in the development of these products?

“Social responsibly,” Walton said simply.

"Obviously, this is very expensive," he said, ”but the companies consider this activity to be an important corporate responsibility, and also important both for how we view ourselves, and our customers view us, as companies.”

Related products

Live Supplier Webinars

Polyphenols tipped to become the way to innovate in Sports Nutrition
Fytexia
Alpha & Omega in Sports Nutrition – Using Omega 3’s and A-GPC to improve performance and recovery.
KD Pharma
Orally bioavailable standardized botanical derivatives in sport nutrition: special focus on recovery in post-intense physical activities
Indena
Collagen in motion: move freely and keep your injuries in check
Leading manufacturer of gelatine and collagen peptides
Life’s too short for slow proteins. Whey proteins hydrolysates: Fast delivery for enhanced performance
Arla Foods Ingredients
What it Takes to Compete and Win in Today’s Sports Nutrition Market
Capsugel
Sports Nutrition Snapshot: Key regional drivers and delivery format innovations
William Reed Business Media
Gutsy performance: How can microbiome modulation help athletes and weekend warriors
William Reed Business Media
Pushing the boundaries: Where’s the line between ‘cutting edge nutrition’ and doping
William Reed Business Media

On demand Supplier Webinars

High-amylose maize starch may reduce the risk of type 2 diabetes: what does this qualified health claim mean?
Ingredion
Balancing Innovation and Risk in Sports Nutrition Ingredients
NSF-International
Explaining bio-hacking: is there a marketing opportunity for food companies?
William Reed Business Media
Personalized Nutrition – how an industry can take part in shaping the future of Nutrition
BASF Nutrition & Health
Find out Nutritional and ingredient lifecycle solutions and strategies!
Roquette
Is the time rIpe for I-nutrition?
William Reed Business Media
The Advantage of Outsourcing Fermentation-based Manufacturing Processes
Evonik Health Care
All supplier webinars